We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current INBX market cap is 1.61B. The company's latest EPS is USD -5.0928 and P/E is -6.69.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 278k | 274k | 17k | 30k | 119k |
| Operating Income | -30M | -35.5M | -43.77M | -41.34M | -45.83M |
| Net Income | -35.33M | -40.92M | -48.92M | -47.05M | -51.79M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 13.21M | 12.89M | 7.23M | 2.19M | 1.8M |
| Operating Income | -43.71M | -67.44M | -76.56M | -129.12M | -219.22M |
| Net Income | -51.4M | -76.12M | -81.77M | -145.23M | -241.36M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 164.85M | 290.88M | 253.72M | 213.17M | 372.73M |
| Total Liabilities | 199.9M | 232.82M | 238.58M | 237.98M | 243.14M |
| Total Equity | -35.05M | 58.06M | 15.13M | -24.81M | 129.6M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 26.49M | 143.74M | 150.45M | 290.88M | 307.89M |
| Total Liabilities | 60.55M | 68.27M | 98.07M | 232.82M | 264.39M |
| Total Equity | -93.57M | 75.47M | 52.38M | 58.06M | 43.5M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -84.7M | -115.3M | -39.94M | -82.24M | -136.49M |
| Investing | -419k | -686k | -23k | -340k | -1.15M |
| Financing | 99.89M | 258.55M | 356k | 1.21M | 201.1M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -32.08M | -47.97M | -80.32M | -115.3M | -193.31M |
| Investing | -1.81M | -1.36M | -809k | -686k | -4.59M |
| Financing | 43.33M | 166.46M | 83.77M | 258.55M | 201.96M |
| Market Cap | 1.61B |
| Price to Earnings Ratio | -6.69 |
| Price to Sales Ratio | 896.05 |
| Price to Cash Ratio | 5.81 |
| Price to Book Ratio | 37.09 |
| Dividend Yield | - |
| Shares Outstanding | 47.39M |
| Average Volume (1 week) | 295.02k |
| Average Volume (1 Month) | 435.52k |
| 52 Week Change | 70.90% |
| 52 Week High | 39.79 |
| 52 Week Low | 14.305 |
| Spread (Intraday) | 1.27 (3.66%) |
| Company Name | Inhibrx Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.inhibrx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
